Drugs / Carboxymethylcellulose
Carboxymethylcellulose
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00243711 | Sep 2005 → Apr 2006 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02455050 | Dec 2014 → Aug 2015 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01459588 | Oct 2011 → Feb 2012 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 44 trials · 1 missed | ||||||
| Phase 4 | NCT05292755 | Apr → May 2022 | dry eye syndrome | University of Florida | Completed | Missed primary |
| Phase 4 | NCT02752763 | Oct 2015 → Mar 2016 | dry eye syndrome | Niğde State Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00987727 | Nov 2009 → Jul 2010 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00386646 | Feb 2004 → Oct 2005 | dry eye syndrome | Chulalongkorn University | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07562594 | Jun → Dec 2026 expected | exposure keratitis | Fatih Sultan Mehmet Training and Research Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05924893 | Jan 2021 → Jun 2022 | corneal ulcer | Minia University | Completed | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1 | NCT06375343 Comparator | Jan 2026 → Jan 2027 expected | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05063422 Background | Aug 2022 → Aug 2023 | — | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02553772 Comparator | Jan → Sep 2016 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01886690 Comparator | Aug 2013 → Aug 2014 | — | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01844388 Comparator | May → Dec 2013 | contact lens corneal edema | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01664949 Comparator | Jan 2013 → May 2014 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01294384 Comparator | May 2011 → Sep 2012 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT07635849 Comparator | Jul 2026 → Jan 2027 expected | dry eye syndrome | Pokhara Academy of Health Sciences, Western Regional Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07676084 Comparator | Jun → Oct 2026 expected | dry eye syndrome | Andover Research Eye Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT04127851 Comparator | Nov 2019 → Jul 2021 | dry eye syndrome | Taejoon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02117687 Comparator | May 2014 → Jan 2015 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT02121847 Background | Apr → Sep 2014 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT01280110 Comparator | Mar → Dec 2011 | dry eye syndrome | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT00938704 Comparator | Jun 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00756678 Comparator | Sep 2008 → Aug 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT02395952 Comparator | Mar 2015 → Feb 2018 | corneal disorder | Milton S. Hershey Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00514852 Comparator | Oct 2007 → Jan 2008 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT00544713 Comparator | Sep 2007 → Jun 2008 | dry eye syndrome | Allergan | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carboxymethylcellulose | “Patients in Group 2 (Tape + Drops) will receive preservative-free lubricant eye drops (carboxymethylcellulose 0.5%, single-dose vial) instilled into both conjunctival fornices...” NCT07562594 ↗21“preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.” NCT02752763 ↗ “carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes” NCT04127851 ↗ “Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.” NCT06375343 ↗ “Carboxymethylcellulose and Glycerin” NCT00756678 ↗ |
| Known as | carboxymethylcellulose sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01294384 ↗ |
| Known as | CMC | “Carboxymethylcellulose (CMC), a common component in artificial tears, has been shown to modify the gut microbiome.” NCT05292755 ↗2“carboxymethylcellulose (CMC) / one drop / two\~six times daily in both eyes” NCT04127851 ↗ “0.5% carboxymethylcellulose (CMC) with purite and CMC alone” NCT00386646 ↗ |
| Known as | OM3 Tear | “Carboxymethylcellulose based eye drop (OM3 Tear)” NCT02553772 ↗ |
| Modality | Other / unclassified | “Carboxymethylcellulose based artificial tear” NCT00544713 ↗ |
| Route | Other | “1 to 2 drops into each eye as needed but at least twice daily” NCT00514852 ↗ |